Zepzelca (Lurbinectedin Vials) 4mg

ZEPZELCA (lurbinectedin) 4mg vials are prescribed for metastatic cancer treatment. This chemotherapy agent targets specific cancer cells to slow disease progression. Store between 2-8°C and use as directed by a healthcare provider. Always consult a medical professional for personalized advice.

Strength

4mg

Pack Size

Storage

2-8°

Manufacturer / TM Owner

Pharma Mar

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

ZEPZELCA is used to treat metastatic small cell lung cancer in adults who have progressed after platinum-based chemotherapy. It belongs to a class of medications called alkylating agents, which work by interfering with cancer cell growth. This drug is typically administered when other treatments have not been effective. It is not a first-line therapy.

Side Effects

Patients may experience fatigue, nausea, or reduced appetite during treatment. Some individuals report changes in taste or mild hair thinning. These effects vary widely and are typically temporary. Hydration and rest can help manage some symptoms.

Precautions & Warnings

ZEPZELCA should be handled with care to avoid exposure. It is important to follow storage guidelines strictly, keeping vials refrigerated between 2-8°C. Avoid direct contact with skin or mucous membranes. Always use protective gear when preparing or administering the medication.

Avoid Interactions

Certain medications, including strong CYP3A inhibitors or inducers, may affect how ZEPZELCA works. Avoid alcohol and consult a healthcare provider before combining with other treatments. Grapefruit products can also interact with this medication. Always disclose all medications to your doctor.

Frequently Asked Questions

ZEPZELCA is used to treat metastatic small cell lung cancer in adults after platinum-based chemotherapy.

ZEPZELCA is given as an intravenous infusion by a healthcare professional in a clinical setting.

Common side effects include fatigue, nausea, and reduced appetite. These effects vary by individual.

No, ZEPZELCA vials must be refrigerated between 2-8°C and protected from light.

Yes, it may interact with CYP3A inhibitors, inducers, or alcohol. Always consult a healthcare provider.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.